Multiple Myeloma
Also known as: Plasma-cell myeloma
Methodology & AI Transparency ⓘ
Multiple Myeloma Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell.
- 2 Real-world patient consensus: Synonyms for Multiple Myeloma (C90.00): Plasma-cell myeloma (Cancer & Oncology).
- 3 Typical cash cost range: Clinicians assessing Multiple Myeloma focus on somatic oncogenic driver in Multiple Myeloma (C90.00: mutations) and targeted history.
- 4 Top reported side effects / signs: Longitudinal Multiple Myeloma monitoring tracks Comprehensive Metabolic & in Multiple Myeloma (C90.00: Organ Function Panel) toward Preserved renal/hepatic clearance (C90.00).
Ask our AI Specialists anything about Multiple Myeloma
What Is Multiple Myeloma?
Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bones. No one knows the exact causes of multiple myeloma, but it is more common in older people and African Americans. It can run in families.
Pathophysiology, Underlying Causes & Clinical Presentation
In Multiple Myeloma (C90.00), physiological disruption stems from somatic oncogenic driver in Multiple Myeloma (C90.00: mutations), Cross-referenced with NIH MeSH (Multiple Myeloma), informing Cancer, Oncology & Supportive Care protocols that track Pathology / Molecular in Multiple Myeloma (C90.00: Genomic Staging) (Guideline-concordant surveillance (C90.00)).
Common Symptoms & Clinical Signs
- • Bone pain, often in the back or ribs
- • Fractures (broken bones)
- • Presentation of Multiple Myeloma (C90.00): abnormality detected early in Multiple Myeloma (C90.00: on age-appropriate screening)
- • Secondary Multiple Myeloma clinical sign: persistent painless lump, in Multiple Myeloma (C90.00: non-healing ulcer/mole change,)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Multiple Myeloma Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C90.00 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Multiple Myeloma (C90.00: Organ Function Panel) | Preserved renal/hepatic clearance (C90.00) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Multiple Myeloma (C90.00: Genomic Staging) | Guideline-concordant surveillance (C90.00) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Multiple Myeloma (C90.00: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C90.00) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Multiple Myeloma
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Elotuzumab Empliciti • RxCUI 1726110 | SLAMF7-directed Immunostimulatory Antibody | 80% | $2.3700 | $ 104.49 /mo |
| Lenalidomide Revlimid • RxCUI 602910 | Thalidomide Analog | 74% | $1.0100 | $ 49.41 /mo |
| Pomalidomide Pomalyst • RxCUI 1369718 | Thalidomide Analog | 84% | $0.2500 | $ 18.63 /mo |
| Lovastatin Mevacor • RxCUI 197905 | HMG-CoA Reductase Inhibitor | 84% | $0.0421 | $ 5.69 /mo |
| Tecfidera (Dimethyl Fumarate) Tecfidera • RxCUI 1373483-B64406006 | Multiple sclerosis Agent | 91% | $0.9402 | $ 9.05 /mo |
| Denosumab Bilprevda, Ospomyv • RxCUI 2723338 | RANK Ligand Inhibitor | 81% | $812.8408 | $ 185.00 /mo |
| Natalizumab-Sztn Tyruko • RxCUI 2725173 | Integrin Receptor Antagonist | 93% | $0.9200 | $ 45.76 /mo |
| Adrenalin(R) Adrenalin(R) Generic • RxCUI 310132 | alpha-Adrenergic Agonist | 75% | $7.7955 | $ 185.00 /mo |
| Zoledronic Acid Reclast • RxCUI 351114 | Bisphosphonate | 74% | $0.4788 | $ 27.89 /mo |
| Copaxone (Glatiramer Acetate) Copaxone • RxCUI 2000007-B68546325 | Multiple sclerosis Agent | 81% | $540.0503 | $ 992.50 /mo |
| Melphalan Hydrochloride Melphalan Hydrochloride Generic • RxCUI 311487 | FDA Prescription Therapeutic Agent | 90% | $0.6000 | $ 32.80 /mo |
| Fluorouracil Tolak, Efudex • RxCUI 105583 | Nucleoside Metabolic Inhibitor | 90% | $0.5853 | $ 16.50 /mo |
| Cladribine Mavenclad • RxCUI 2122634 | Purine Antimetabolite | 92% | $2.4900 | $ 11362.63 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Multiple Myeloma)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy of natalizumab in secondary progressive multiple sclerosis: analysis of: What a 1,156-Participant Study Found After accounting for therapeutic lag and differences between ASCEND and SPECTRIMS trials, natalizumab, compared. Journal of neurology, neurosurgery, and psychiatry • 2025-09-12 • Phase III Randomized Trial | N = 1,156 | 96/100 | PMID 40050011 ↗ |
| New Insights on Utility of Progression Independent of Relapse Activity as a Trial Outcome in: What a 2,113-Participant Study Found Our analysis included 2,113 participants, 42.4% of whom developed radiologic disease activity during follow-up. Neurology • 2025-01-28 • Phase III Randomized Trial | N = 2,113 | 96/100 | PMID 39960455 ↗ |
| New Insights on Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for: What a 1,057-Participant Study Found Clinical and radiological outcomes generally favored DRF versus IFN. Journal of comparative effectiveness research • 2024-10-15 • Phase III Randomized Trial | N = 1,057 | 96/100 | PMID 39158844 ↗ |
| New Insights on Safety profile of efgartigimod from global clinical trials across multiple: What a 715-Participant Study Found Across clinical trials in IgG-mediated autoimmune diseases, efgartigimod was well tolerated with similar safety profiles regardless of dosing regimen. Expert review of clinical immunology • 2025-05-15 • Phase III Randomized Trial | N = 715 | 93/100 | PMID 40296516 ↗ |
| New Insights on Benefits and safety of Ponesimod Compared with Teriflunomide in Female Patients: What a 363-Participant Study Found Conclusions: Analyses demonstrate the real-world benefits and safety of ponesimod, versus active comparator, for women with relapsing MS, supporting data-informed decision-making for women with MS. Journal of women's health (2002) • 2024-04-15 • Phase III Randomized Trial | N = 363 | 93/100 | PMID 38301149 ↗ |
Multiple Myeloma Patient Community & “People Like Me” Threads
Filter Multiple Myeloma community threads and patient logs by age, biological sex, dosage, and treatment duration.